ResMed Inc. 10-Q Summary: Quarter Ended March 31, 1998
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation holding ResMed Holdings Ltd., an Australian-based designer and manufacturer of devices for sleep-disordered breathing. The report covers the three and nine-month periods ended March 31, 1998. Principal manufacturing is located in Australia, with major distribution in the U.S., U.K., and Europe.
Key Financial Metrics
| Metric | 3 Months Ended Mar 31, 1998 | 9 Months Ended Mar 31, 1998 |
|---|---|---|
| Net Revenue | $17.1 million | $47.2 million |
| Gross Profit | $11.0 million (64% margin) | $30.5 million (65% margin) |
| Net Income | $3.1 million | $7.6 million |
| Diluted EPS | $0.42 | $1.02 |
| Cash & Equivalents | $11.8 million (Balance Sheet) | $11.8 million (Balance Sheet) |
| Working Capital | $31.7 million | $31.7 million |
| Long-Term Debt | $243,000 | $243,000 |
| Operating Cash Flow | N/A | $3.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 37% ($4.6 million) for the quarter and 34% ($12.0 million) for the nine-month period compared to the prior year. Growth was driven by increased unit sales of flow generators and accessories in North America and Europe.
- Margin Expansion: Gross profit margins improved to 64% (quarter) and 65% (nine months) from 59% and 58% respectively in the prior year. This was attributed to higher sales of high-margin products and the devaluation of the Australian dollar.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 30% for the quarter due to an increase in sales personnel (from 103 to 136). R&D expenses increased 21% for the quarter due to new product development.
- Other Income Volatility: Other income (expenses) net turned to a loss of $163,000 for the nine-month period, down from $2.4 million in the prior year, primarily due to foreign currency losses from the devaluation of the Australian dollar, partially offset by $1.25 million in licensing fees from Invacare.
- Capital Expenditures: Capital spending surged to $8.6 million for the nine months ended March 31, 1998, compared to $2.7 million in the prior year, largely due to the construction of a new Australian manufacturing facility.
Outlook, Risks, and Contingencies
- Capital Needs: Management anticipates expending approximately $9.0 million over the next twelve months for the new manufacturing facility and computer systems, funded by operating cash flows and existing resources.
- Legal Proceedings: The Company is engaged in significant patent litigation against Respironics in the U.S. regarding four patents. A partial summary judgment was granted to Respironics regarding one patent, which ResMed intends to appeal. Additionally, Respironics and its Australian distributor have filed a claim in Australia alleging unfair trade practices, seeking approximately $730,000 in damages. The Company expects to incur ongoing legal costs.
- Currency Risk: The Company has substantial exposure to the Australian dollar regarding manufacturing and R&D costs. While hedging strategies (foreign currency options) are in place, exchange rate fluctuations continue to impact consolidated revenue and margins.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing patent litigation with Respironics in both the U.S. and Australia.
- Monitor the progress and cost overruns of the new Australian manufacturing facility construction.
- Assess the sustainability of gross margin improvements given the volatility of the Australian dollar exchange rate.
- Review the effectiveness of foreign currency hedging strategies in mitigating future exchange rate losses.
- Confirm the timeline for the appeal of the partial summary judgment granted to Respironics.